Healthcare >> CEO Interviews >> March 17, 2003
STEVEN A. ELMS, Chairman of Oculex Pharmaceuticals, Inc., is a
Managing Director of the Perseus-Soros BioPharmaceutical Fund.
For five years prior to joining Perseus-Soros, Mr. Elms was a
Principal in the Life Science Investment Banking group of
Hambrecht & Quist (now J.P. Morgan H&Q). During his five years at
H&Q, Mr. Elms was involved in over 60 financing and M&A
transactions, helping clients raise over $3.3 billion in capital.
Additional healthcare sector experience includes sales and
marketing with Marion Laboratories and consulting for The
Wilkerson Group. Mr. Elms also serves as a director of other
Perseus-Soros portfolio companies. He received an MBA from
Northwestern's Kellogg Graduate School of Management and a BA in
Human Biology from Stanford University. Profile
DAVID A. WEBER, PhD, has served as Executive Vice President for
Oculex Pharmaceuticals, Inc. since 2000. Prior to joining Oculex,
Dr. Weber was Vice President, Research and Development at Oral-B
Laboratories, where he oversaw worldwide product development,
regulatory, and clinical operations for both professional and
consumer medical device and drug products. Previously, Dr. Weber
was a Senior Scientist in Health Care Product Development at The
Procter & Gamble Company, with responsibilities for both ethical
and consumer pharmaceuticals. Dr. Weber received his BS and MS
degrees in Biological Sciences from Wichita State University and
his PhD from Creighton University School of Medicine. Profile
things you're doing now?
Dr. Weber: Oculex Pharmaceuticals is a privately held ophthalmic
drug delivery and specialty
